Literature DB >> 10961432

Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach.

K Iqbal1, A D Alonso, J A Gondal, C X Gong, N Haque, S Khatoon, A Sengupta, J Z Wang, I Grundke-Iqbal.   

Abstract

Neurofibrillary degeneration is a key histopathological brain lesion of Alzheimer disease (AD) and related neurodegenerative disorders such as frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17), commonly referred to as tauopathies. Microtubule associated protein (MAP) tau, which is a major MAP of a normal mature neuron is abnormally hyperphosphorylated in tauopathies and is the major protein subunit of paired helical filaments (PHF)/straight filaments (SF) which accumulate in the soma (as neurofibrillary tangles) and dystrophic neurites (as neuropil threads and as dystrophic neurites surrounding the beta-amyloid core in neuritic plaques in AD) of the affected neurons. Unlike normal tau which stimulates assembly and stabilizes microtubules, the abnormally hyperphosphorylated tau inhibits assembly and disrupts microtubules. The abnormally hyperphosphorylated tau competes with tubulin/microtubules in associating with normal tau, MAP1 and MAP2. This sequestration of normal MAPs by the abnormal tau results in the breakdown of the microtubules. The association of the abnormal tau with normal tau and not with MAP1 or MAP2 results in the formation of tangles of tau filaments. All these toxic properties of the abnormally hyperphosphorylated tau are eliminated by its enzymatic dephosphorylation. Activities of phosphoseryl/phosphothreonyl protein phosphatases (PP)-2A and PP-1 which can dephosphorylate the abnormal tau to a normal-like state are compromised in AD brain. Dephosphorylation by PP-2A and PP-2B and to a lesser extent by PP-1 restores the normal microtubule assembly promoting activity in AD P-tau in vitro. Neurofibrillary tangles of PHF isolated from AD brain are also dissociated on in vitro dephosphorylation with PP-2A, and the tau released by this treatment can stimulate microtubule assembly. Thus, it appears that the abnormal hyperphosphorylation of tau leads to neurodegeneration through breakdown of the microtubule network and that the abnormal tau on association with normal tau forms neurofibrillary tangles of tau filaments i.e. PHF/SF. Increase in tau phosphatase activity is a promising approach to inhibit neurofibrillary degeneration and thereby the diseases characterized by this lesion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961432     DOI: 10.1007/978-3-7091-6781-6_22

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  17 in total

Review 1.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

2.  Synthesis, stereochemical analysis, and derivatization of myricanol provide new probes that promote autophagic tau clearance.

Authors:  Mackenzie D Martin; Laurent Calcul; Courtney Smith; Umesh K Jinwal; Sarah N Fontaine; April Darling; Kent Seeley; Lukasz Wojtas; Malathi Narayan; Jason E Gestwicki; Garry R Smith; Allen B Reitz; Bill J Baker; Chad A Dickey
Journal:  ACS Chem Biol       Date:  2015-01-30       Impact factor: 5.100

3.  ω-3PUFAs prevent MK-801-induced cognitive impairment in schizophrenic rats via the CREB/BDNF/TrkB pathway.

Authors:  Mao-Sheng Fang; Xing Li; Hong Qian; Kuan Zeng; Meng Ye; Yong-Jie Zhou; Hui Li; Xiao-Chuan Wang; Yi Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

Review 4.  Molecular and cellular mechanism of okadaic acid (OKA)-induced neurotoxicity: a novel tool for Alzheimer's disease therapeutic application.

Authors:  Pradip K Kamat; Shivika Rai; Supriya Swarnkar; Rakesh Shukla; Chandishwar Nath
Journal:  Mol Neurobiol       Date:  2014-04-08       Impact factor: 5.590

Review 5.  Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration.

Authors:  D Allan Butterfield; Sarita S Hardas; Miranda L Bader Lange
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 6.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 7.  M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Shangtong Jiang; Yanfang Li; Cuilin Zhang; Yingjun Zhao; Guojun Bu; Huaxi Xu; Yun-Wu Zhang
Journal:  Neurosci Bull       Date:  2014-03-03       Impact factor: 5.203

Review 8.  Cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Xiaojing Sui; Jianjun Liu; Xifei Yang
Journal:  Neurosci Bull       Date:  2014-04-15       Impact factor: 5.203

Review 9.  Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion.

Authors:  Khalid Iqbal; Alejandra del C Alonso; Ezzat El-Akkad; Cheng-Xin Gong; Niloufar Haque; Sabiha Khatoon; Jin-Jing Pei; Ichiro Tsujio; Jian-Zhi Wang; Inge Grundke-Iqbal
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

10.  Twist1-Induced Epithelial Dissemination Requires Prkd1 Signaling.

Authors:  Dan Georgess; Veena Padmanaban; Orit Katarina Sirka; Kester Coutinho; Alex Choi; Gabriela Frid; Neil M Neumann; Takanari Inoue; Andrew J Ewald
Journal:  Cancer Res       Date:  2019-11-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.